Sreedhar A Mandayam, MD, MPH, MBA, FASN
Department of Emergency Medicine, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Professor, Department of Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1995 | Bangalore Medical College, Bangalore University, Bangalore, IND, MBBS, Doctor of Medicine |
Experience & Service
Academic Appointments
Assistant Professor, Division of Nephrology, Baylor College of Medicine, Houston, TX, 2009 - 2012
Assistant Professor, Division of Internal Medicine, The University of Kansas Medical Center, Witchita, KS, 2006 - 2009
Administrative Appointments/Responsibilities
Vice Chair, Baylor College of Medicine, Houston, TX, 2016 - 2018
Other Appointments/Responsibilities
Member, Baylor College of Medicine,Eisenberg Center for Clinical Decisions & Communication Science,, Houston, TX, 2011 - Present
Grant & Contract Support
| Title: | Epidemiology, Health Services |
| Funding Source: | Institutional Funding |
| Role: | Co-Investigator |
| Title: | Effect of Auryxia on ESA Utilization in ESRD patients with high Ferritin and low Transferrin saturation |
| Funding Source: | Keryx Biopharmaceuticals |
| Role: | Co-Investigator |
| Title: | Pegloticase for treatment of Tumor Lysis Syndrome: Horizon Biopharmaceuticals |
| Funding Source: | Horizon Biopharmaceuticals |
| Role: | Principal Investigator |
| Title: | Cell free DNA monitoring in Kidney transplant recipients undergoing immunotherapy for cancer |
| Funding Source: | Care DX |
| Role: | Principal Investigator |
| Title: | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| Title: | Effect of Ferric Citrate on ESRD patients with elevated Ferritin |
| Funding Source: | Akebia Therapeutics |
| Role: | Co-Principal Investigator |
Patient Reviews
CV information above last modified November 15, 2023